All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
CAMMA-2 Cohort A1: Cevostamab in patients with RRMM and prior BCMA-targeted ADC or CAR T-cell therapy
Bookmark this article
|
CAMMA-2 (NCT05535244) is an ongoing phase I/II study evaluating the efficacy and safety of cevostamab (a FcRH5xCD3 bispecific antibody) in patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class refractory and have received a prior BCMA-targeted agent. Analysis of Cohort A1 (n = 21), which enrolled patients with prior exposure to BCMA-targeted antibody–drug conjugate (ADC) or chimeric antigen receptor (CAR) T-cell therapy, was presented at EHA 2024 by Shaji Kumar. |
| Key learnings: |
|
In CAMMA-2, following treatment with cevostamab, the overall response rate (ORR) for Cohort A1 was 67%, with 38% achieving very good partial response (VGPR). |
|
Response rates were higher in the prior CAR T-cell group (ORR, 73%; VGPR, 55%; n = 11) compared with the prior ADC group (ORR, 60%; VGPR, 20%; n = 10). |
|
Adverse events (AEs) were consistent with the known safety profile of cevostamab, with no fatal AEs. |
|
All cytokine release events were Grade 1–2 and affected 71% of patients overall (90% who received prior ACD and 55% who received prior CAR T-cell therapy). |
|
Cevostamab shows efficacy in heavily pre-treated RRMM patients with prior BCMA-targeted ADC or CAR T-cell exposure, with a clinically manageable safety profile. These findings support further investigation and potential integration of cevostamab into clinical practice for this patient population. |
- Kumar S. Cevostamab in patients with RRMM who are triple-class refractory and have received prior BCMA-targeted or ADC or CAR T-cell: Initial results from the phase I/II CAMMA-2 study. Presentation #S210. Presented at: European Hematology Association 2024 Hybrid Congress; Jun 13–16, 2024; Madrid, ES.
Your opinion matters
2 votes - 43 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox